Loading
A start-up developing a low-cost blood test that reads a few proteins, with separate panels for men and women, to detect many early cancers.
Novelna, led by founder and chief executive Ashkan Afshin, published its discovery study in BMJ Oncology in 2024. Its Palo Alto location is reported by trade press rather than its own website; its founding year was not found.
An experimental blood test that reads a handful of proteins, with different panels for men and women, to find many early cancers; so far it has been tried only on a few hundred stored samples.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/